Category - Developments

Developments

PharmaJet, Mundipharma team up to boost access to needle-free drug technology

PharmaJet and Mundipharma have inked an exclusive partnership to market and distribute PharmaJet’s Tropis and Stratis needle-free drug-delivery devices to more than 120 markets around the world. The devices are designed...

July 26, 2018

Developments

Synexus in U.S. registry study on brain ageing

Synexus, a leading global network of research sites, is collaborating with the University of Exeter in the UK to launch one of the largest, registry-based research initiatives in the U.S. to help understand how healthy...

July 25, 2018

Developments

Respinova wins Chiesi Spain and Richi Entrepreneurs second call

Israel-based Respinova has won the second grant offered by Chiesi Spain and Richi Entrepreneurs to promote an innovative project that directly impacts treatment and quality of life of patients with chronic obstructive...

July 24, 2018

Developments

Imagin Medical reports favorable results from i/Blue imaging study

Imagin Medical (CSE:IME; OTCQB:IMEXF) reported favorable results in a 10-subject investigator-sponsored research study at the University of Rochester Medical Center (URMC) using the i/Blue Imaging System, an important...

July 18, 2018

Developments

Profound Medical uplisting to TSX

Profound Medical (TSXV:PRN; OTCQX:PRFMF) has received final approval to list its common shares on the Toronto Stock Exchange, effective at the opening on July 13, 2018. The stock will continue to trade under the symbol...

July 11, 2018

Developments

Parkinson’s prevalence to hit 1.2 million people in U.S. by 2030

A study published in the scientific journal, npj Parkinson’s Disease, estimates that 930,000 people in the U.S. will be living with the disease by 2020, further increasing to 1.2 million people by 2030. “Our...

July 10, 2018

Developments

IntelGenx receives Canadian patent notice for Loxapine VersaFilm

The Canadian Intellectual Property Office (“CIPO”) has issued a notice of allowance for IntelGenx’s (TSXV:IGX; OTCQX:IGXT) first Canadian patent application for its VersaFilm technology. Entitled, “Loxapine Film Oral...

July 5, 2018

Developments

ASLAN Pharma applies for first-in-man study of ASLAN004

ASLAN Pharmaceuticals (TPEx:6497; NASDAQ:ASLN) has applied to the Singapore Health Sciences Authority to conduct a Phase 1 clinical trial of ASLAN004. The single ascending dose study will recruit healthy volunteers and...

July 3, 2018

Developments

Urotronic Optilumedrug-coated balloon catheter licensed in Canada

Closely-held Urotronic of Plymouth, MN has received a license to begin treating urethral strictures with its Optilume drug-coated balloon (DCB) catheter in Canada. “We are quite excited to see this come to market,” Dr...

June 28, 2018

Developments

Aquinox Pharma AQX-1125 fails Phase 3 trial

Aquinox Pharmaceuticals (NASDAQ:AQXP) announced that the Phase 3 LEADERSHIP 301 clinical trial, evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome, failed to...

June 27, 2018

Category - Developments

PharmaJet, Mundipharma team up to boost access to needle-free drug technology

Synexus in U.S. registry study on brain ageing

Respinova wins Chiesi Spain and Richi Entrepreneurs second call

Imagin Medical reports favorable results from i/Blue imaging study

Profound Medical uplisting to TSX

Parkinson’s prevalence to hit 1.2 million people in U.S. by 2030

IntelGenx receives Canadian patent notice for Loxapine VersaFilm

ASLAN Pharma applies for first-in-man study of ASLAN004

Urotronic Optilumedrug-coated balloon catheter licensed in Canada

Aquinox Pharma AQX-1125 fails Phase 3 trial

General

More